Nuveen
TARA icon

Nuveen’s Protara Therapeutics TARA Stock Holding History

Nuveen’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
72,610
+8,750
+14% +$41.6K ﹤0.01% 3530
2026
Q1 		$333K Sell
63,860
-22,641
-26% -$134K ﹤0.01% 2984
2025
Q4 		$461K Sell
86,501
-196,980
-69% -$1.1M ﹤0.01% 2909
2025
Q3 		$1.23M Buy
283,481
+181,880
+179% +$589K ﹤0.01% 2524
2025
Q2 		$308K Buy
+101,601
New +$350K ﹤0.01% 3041
2021
Q2 		– Sell
-13,940
Closed -$219K – 3527
2021
Q1 		$219K Sell
13,940
-10,707
-43% -$199K ﹤0.01% 3215
2020
Q4 		$597K Buy
+24,647
New +$531K ﹤0.01% 2994

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Nuveen's TARA Position: Q2 2026 in Review

Nuveen increased its Protara Therapeutics (TARA) stake by 14% in Q2 2026, buying an estimated $41.6K and bringing the position to 72,610 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #3530.

Nuveen first reported a position in TARA in Q4 2020 and has held it in 7 quarters since. The position peaked at $1.23M in Q3 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Nuveen held 72,610 shares of Protara Therapeutics worth $277K as of Q2 2026.
  • Nuveen bought 8,750 Protara Therapeutics shares in Q2 2026, an estimated $41.6K.
  • Protara Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3530 holding.
  • Nuveen first reported a position in Protara Therapeutics in Q4 2020 and has held it in 7 quarters since.
  • Nuveen's Protara Therapeutics position peaked at $1.23M in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.